Evidence map›Paper›PMID 42791320›Full record

ArticleBritish journal of cancer2026

Correction: Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial.

Maarten A Huismans, Eelke H Gort, Lisa T van der Heijden, Sermin M Guven Mese, Helena M Klein Wolterink, Manon N G J A Braat, Sjoerd G Elias, Filip Y F L de Vos, Lot A Devriese, Henk M W Verheul and 7 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Maarten A HuismansDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0003-1556-0820
Eelke H GortDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Lisa T van der HeijdenDepartment of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Sermin M Guven MeseDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Helena M Klein WolterinkDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Manon N G J A BraatDepartment of Radiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Sjoerd G EliasDepartment of Epidemiology, Julius Center for Health Sciences and Primary Care, Utrecht University, Utrecht, the Netherlands.
Filip Y F L de VosDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0002-9082-5991
Lot A DevrieseDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Henk M W VerheulDepartment of Medical Oncology, Erasmus Medical Center, Erasmus University Rotterdam, Rotterdam, the Netherlands.
Frans L OpdamEarly Drug Development Center, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Miriam KoopmanDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0003-1550-1978
Hilde H NienhuisDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Heleen A CrommelinDepartment of Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Hugo J G SnippertCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0002-4189-5213
Alwin D R HuitemaDepartment of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jeanine M L RoodhartDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. j.roodhart@umcutrecht.nl.ORCID http://orcid.org/0000-0003-1398-8970

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42791320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.